Altogether our work suggests that inhibition (or inactivation) of ZBTB38 or USP9X expression may be a new strategy to enhance the clinical efficacy of DNMTi in hematological and non-hematological cancers. The gene discussed is ZBTB38; the disease is hematopoietic and lymphoid cell neoplasm.